This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
by Zacks Equity Research
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
GKOSPositive Net Change COOPositive Net Change WSTPositive Net Change GMEDPositive Net Change
medical medical-devices
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
by Sridatri Sarkar
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
IDXXPositive Net Change DXCMPositive Net Change INGNPositive Net Change
medical
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
by Sridatri Sarkar
ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.
ABTPositive Net Change ISRGPositive Net Change TMOPositive Net Change
medical
Should You Continue to Retain PAHC Stock in Your Portfolio?
by Zacks Equity Research
Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.
PAHCPositive Net Change TFXPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. RL, AMP, HALO and NVDA are some such stocks.
NVDAPositive Net Change AMPPositive Net Change RLPositive Net Change HALOPositive Net Change
artificial-intelligence consumer-discretionary finance medical tech-stocks
Healthcare ETFs Are Looking Up: Here's Why
by Sanghamitra Saha
Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.
SPYPositive Net Change XLVPositive Net Change PJPPositive Net Change IHEPositive Net Change XPHPositive Net Change BBHPositive Net Change
etfs medical
New Strong Sell Stocks for August 19th
by Zacks Equity Research
ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.
ALPMYPositive Net Change ASEKYPositive Net Change ATSPositive Net Change
auto-tires-trucks industrial-products medical
Ecolab's CoolIT Deal Raises AI Upside but Also Debt and Cost Risks
by Harshit Gupta
ECL's $4.75B CoolIT deal expands its AI data-center cooling opportunity, but higher debt and financing costs raise execution risks.
ECLPositive Net Change NVTNegative Net Change VRTNegative Net Change
medical medical-devices
Is Ecolab Stock Worth Buying as Growth Rises but Debt Risk Builds?
by Harshit Gupta
ECL's accelerating High-Tech, Digital and Life Sciences growth supports its outlook, but rising debt and financing costs keep the buy case cautious.
ECLPositive Net Change CLXPositive Net Change PNRPositive Net Change
medical medical-devices
Ecolab Rallies 12.2% in 3 Months as High-Tech Growth Gains Momentum
by Harshit Gupta
ECL's 12.2% three-month rally is backed by High-Tech, Digital and Life Sciences growth, firmer pricing and a higher 2026 earnings outlook.
ECLPositive Net Change PNRPositive Net Change STEPositive Net Change
medical medical-devices